
Tim Sauer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10074824/publications.pdf Version: 2024-02-01



TIM SALLED

#	Article	IF	CITATIONS
1	Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells. Cancer Discovery, 2017, 7, 1238-1247.	9.4	204
2	Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1. Molecular Therapy, 2017, 25, 2202-2213.	8.2	109
3	CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity. Blood, 2021, 138, 318-330.	1.4	98
4	Current Challenges in Providing Good Leukapheresis Products for Manufacturing of CAR-T Cells for Patients with Relapsed/Refractory NHL or ALL. Cells, 2020, 9, 1225.	4.1	40
5	Effects of realistic e-learning cases on students' learning motivation during COVID-19. PLoS ONE, 2021, 16, e0249425.	2.5	36
6	Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia. Blood Cancer Journal, 2021, 11, 164.	6.2	29
7	MYST2 acetyltransferase expression and Histone H4 Lysine acetylation are suppressed in AML. Experimental Hematology, 2015, 43, 794-802.e4.	0.4	19
8	Modeling cytokine release syndrome. Nature Medicine, 2018, 24, 705-706.	30.7	18
9	Infection Complications after Lymphodepletion and Dosing of Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia or B Cell Non-Hodgkin Lymphoma. Cancers, 2021, 13, 1684.	3.7	17
10	Sensitivity and Specificity of CD19.CAR-T Cell Detection by Flow Cytometry and PCR. Cells, 2021, 10, 3208.	4.1	13
11	<scp>CD33</scp> â€directed immunotherapy with thirdâ€generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and <scp>CD33</scp> â€edited acute myeloid leukemia and hematopoietic stem and progenitor cells. International Journal of Cancer, 2022, 150, 1141-1155.	5.1	13
12	Chimeric Antigen Receptor Signaling Domains Differentially Regulate Proliferation and Native T Cell Receptor Function in Virus-Specific T Cells. Frontiers in Medicine, 2018, 5, 343.	2.6	12
13	Combining selective inhibitors of nuclear export (SINEs) with chimeric antigen receptor (CAR) TÂcells for CD19‑positive malignancies. Oncology Reports, 2021, 46, .	2.6	12
14	Current challenges for CAR T ell therapy of acute myeloid leukemia. Transfusion, 2019, 59, 1171-1173.	1.6	7
15	Venetoclax-Azacitidine As Salvage Therapy and Bridge to Allogeneic Cell Transplantation in Relapsed/Refractory AML Compared to Historical Data of the SAL Registry Study. Blood, 2021, 138, 4418-4418.	1.4	3
16	Characteristics and Outcome of Elderly Patients (>55 Years) with Acute Lymphoblastic Leukemia. Cancers, 2022, 14, 565.	3.7	3
17	Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML. Trials, 2021, 22, 765.	1.6	2
18	Leukemic Stem Cells of Monocytic AMLs Are Not-Resistant to BCL-2 Inhibition. Blood, 2021, 138, 3469-3469.	1.4	1

TIM SAUER

#	Article	IF	CITATIONS
19	Prediction of Complete Remission and Survival in Acute Myeloid Leukemia Using Supervised Machine Learning. Blood, 2021, 138, 108-108.	1.4	1
20	DNA Methyltransferase 3B (DNMT3B) Protein Expression Predicts Survival in Patients with Acute Myeloid Leukemia (AML). Blood, 2012, 120, 1395-1395.	1.4	0
21	Loss Of H3K27 Trimethylation (H3K27me3) Associates With a Multi Drug Resistance Phenotype In Acute Myeloid Leukemia (AML). Blood, 2013, 122, 1253-1253.	1.4	0
22	Th22 and Tfh Cell Elevation Is Associated with Clinical Response of Photopheresis Therapy in Patients with Steroid-Refractory/ Resistant Graft-Versus-Host Disease (GvHD). Blood, 2021, 138, 1810-1810.	1.4	0